Results 301 to 310 of about 197,800 (388)

Longitudinal Alzheimer’s Disease Progression Modelling via Hybrid Vision Transformers and Recurrent Neural Networks With Cross‐Modal Feature Fusion

open access: yesExpert Systems, Volume 43, Issue 3, March 2026.
ABSTRACT Modelling the evolution of Alzheimer's disease (AD) requires a thorough spatiotemporal study of longitudinal neuroimaging data. We propose in this paper a novel deep learning framework that uses a parallel combination of Recurrent Neural Networks (RNNs) and Vision Transformers (ViT) to extract temporal disease dynamics and spatial structural ...
Sahbi Bahroun, Gwanggil Jeon
wiley   +1 more source

Eye‐Tracking‐Based Cognitive Assessment Predicts the Risk of Memory Decline: A Community‐Based Cohort Study

open access: yesGeriatrics &Gerontology International, Volume 26, Issue 3, March 2026.
Eye‐tracking‐based cognitive assessment (ETCA) is a novel screening tool for dementia. In this community‐based longitudinal study, we demonstrated the ETCA's performance in predicting future cognitive decline, which could make a substantial contribution to the prevention of dementia.
Mizuki Katsuhisa   +13 more
wiley   +1 more source

The potential role of sleep quality in the relationship between glymphatic function and migraine frequency: Insights from a cross‐sectional study

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 576-583, March 2026.
Abstract Objective This study aimed to explore the association between glymphatic function, as assessed by the diffusion tensor imaging along perivascular space (DTI‐ALPS) index, and headache frequency in individuals with migraine. Additionally, it evaluated whether sleep quality modulates this relationship.
Raffaele Ornello   +9 more
wiley   +1 more source

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

open access: yesJournal of the American Geriatrics Society, Volume 74, Issue 3, Page 636-647, March 2026.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy